Virpax Pharmaceuticals CEO Anthony Mack's 2022 pay rises 3% to $784K
Virpax Pharmaceuticals reports 2022 executive compensation
By ExecPay News
Published: December 7, 2023
Virpax Pharmaceuticals reported fiscal year 2022 executive compensation information on December 7, 2023.
In 2022, three executives at Virpax Pharmaceuticals received on average a compensation package of $512K, a 4% increase compared to previous year.
Average pay of disclosed executives at Virpax Pharmaceuticals
Anthony Mack, Chief Executive Officer, received $784K in total, which increased by 3% compared to 2021. 60% of Mack's compensation, or $467K, was in salary. Mack also received $79K in option awards and $238K in stock awards.
Christopher Chipman, Chief Financial Officer, received a compensation package of $467K, which increased by 13% compared to previous year. 63% of the compensation package, or $296K, was in salary.
Jeffrey Gudin, Chief Medical Officer, earned $285K in 2022, a 6% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on December 7, 2023.